ICAM-1 as a molecular target for triple negative breast cancer

• Type of Material: Article
• Authors: Peng Guo, City College of New York; Jing Huang, Emory University; Liya Wang, Emory University; Di Jia, Boston Childrens Hospital; Jiang Yang, Boston Childrens Hospital; Deborah A. Dillon, Brigham & Womens Hospital; David Zurakowski, Boston Childrens Hospital; Hui Mao, Emory University; Marsha A. Moses, Boston Childrens Hospital; Debra T. Auguste, City College of New York
• Language: English
• Date: 2014-10-14
• Publisher: National Academy of Sciences
• Publication Version: Final Published Version
• Copyright Statement: Copyright © 2020 National Academy of Sciences.
• Final Published Version (URL): http://dx.doi.org/10.1073/pnas.1408556111
• Title of Journal or Parent Work: Proceedings of the National Academy of Sciences of the United States of America
• Volume: 111
• Issue: 41
• Start Page: 14710
• End Page: 14715
• Grant/Funding Information: H.M. acknowledges support from the NIH (5R01CA154846-02 and 1P50CA128301-01A1).; D.T.A. acknowledges the support of the National Institutes of Health (NIH; National Cancer Institute Grant 1DP2CA174495)
• Keywords: IRON-OXIDE NANOPARTICLES; RECEPTORS; INTERCELLULAR-ADHESION MOLECULE-1; INFLAMMATION; RANDOMIZED PHASE-II; Science & Technology - Other Topics; COMBINATION; EXPRESSION; MONOCLONAL-ANTIBODY; ENLIMOMAB; Science & Technology; Multidisciplinary Sciences; CETUXIMAB
• Research Categories: Engineering, Biomedical

Abstract

Triple negative breast cancers (TNBCs) have a high mortality rate owing to aggressive proliferation and metastasis and a lack of effective therapeutic options. Herein, we describe the overexpression of intercellular adhesion molecule-1 (ICAM-1) in human TNBC cell lines and tissues, and demonstrate that ICAM-1 is a potential molecular target and biomarker for TNBC therapy and diagnosis. We synthesized ICAM-1 antibody-conjugated iron oxide nanoparticles (ICAM-IONPs) as a magnetic resonance imaging (MRI) probe to evaluate tumor targeting. Quantitative analysis of ICAM-1 surface expression predicted the targeting capability of ICAM-IONPs to TNBC cells. MRI of the TNBC xenograft tumor after systemic administration of ICAM-IONPs, coupled with iron quantification and histology, demonstrated a significant and sustained MRI contrast enhancement and probe accumulation in tumors with ICAM-1 overexpression relative to control. Identification of ICAM-1 as a TNBC target and biomarker may lead to the development of a new strategy and platform for addressing a critical gap in TNBC patient care.